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• Functional dyspepsia is one of the most common conditions encountered in clinical 
practice 
• There is a lack of guidance for clinicians in guiding diagnosis and treatment of this 
prevalent condition 
• No treatments are currently approved for the treatment of functional dyspepsia in 
Europe 
 
What is new here 
• A Delphi panel consisting of 41 experts from 22 European countries established 
the level of consensus on 87 statements regarding functional dyspepsia. 
• The statements reaching consensus serve to guide clinicians in recognizing, 
diagnosing and treating FD in clinical practice. 
• Endoscopy is mandatory for establishing a firm diagnosis of functional dyspepsia 
D, but in primary care patients without alarm symptoms or risk factors can be 
managed without endoscopy.  
• H. pylori status should be determined in every patient with dyspeptic symptoms and 
H. Pylori positive patients should receive eradication therapy.  
• Proton pump inhibitor-therapy is considered an effective therapy for FD, but no 






Background: Functional dyspepsia (FD) is one of the most common conditions in 
clinical practice. In spite of its prevalence, FD is associated with major uncertainties in 
terms of its definition, underlying pathophysiology, diagnosis, treatment and prognosis. 
 
Methods: A Delphi consensus was initiated with 41 experts from 22 European 
countries who conducted a literature summary and voting process on 87 statements. 
Quality of evidence was evaluated using grading of recommendations assessment, 
development and evaluation (GRADE) criteria. Consensus (defined as >80% 
agreement) was reached for 36 statements.  
 
Results: The panel agreed with the definition in terms of its cardinal symptoms (early 
satiation, postprandial fullness, epigastric pain and epigastric burning), its subdivision 
into epigastric pain syndrome and postprandial distress syndrome, and the presence 
of accessory symptoms (upper abdominal bloating, nausea, belching) and overlapping 
conditions. Also well accepted are the female predominance of FD, its impact on quality 
of life and health costs, and acute gastrointestinal infections and anxiety as risk factors. 
In terms of pathophysiological mechanisms, the consensus supports a role for 
impaired gastric accommodation, delayed gastric emptying, hypersensitivity to gastric 
distention, H. Pylori infection and altered central processing of signals from the 
gastroduodenal region. There is consensus that endoscopy is mandatory for 
establishing a firm diagnosis of FD, but that in primary care patients without alarm 
symptoms or risk factors can be managed without endoscopy. There is consensus that 
H. pylori status should be determined in every patient with dyspeptic symptoms and H. 
Pylori positive patients should receive eradication therapy. Also, proton pump inhibitor-
therapy is considered an effective therapy for FD, but no other treatment approach 
reached consensus. The long-term prognosis and life expectancy are favorable. 
 
Conclusions and Inferences: A multinational group of European experts summarized 







Functional dyspepsia (FD), defined by the presence of recurrent or chronic epigastric 
symptoms in the absence of organic disease likely to explain them, is one of the most 
common conditions seen in clinical practice (1, 2). In spite of its prevalence, FD is 
associated with major uncertainties, as definitions and the symptom spectrum of FD 
have evolved over time (3), the differential diagnosis is very broad (1), the optimal 
diagnostic work-up has not been defined (4,5) and there is a lack of available 
treatments with established efficacy (6,7). 
 
The aim of this project was to develop a European consensus on the definition, 
pathophysiological concepts, diagnosis, management and prognosis of FD. The 
results of this consensus can offer the clinician guidance in diagnosing and managing 




The European Society for Neurogastroenterology and Motility (ESNM) initiated a 
Delphi process, funded by United European Gastroenterology, to develop consensus 
statements on different aspects of FD in collaboration with other European societies. 
The Delphi approach, which combines the principles of evidence-based medicine, 
supported by systematic literature reviews and a voting process, aims at determining 
consensus for complex problems in medicine for which evidence from controlled trials 
is lacking (8). 
 
The principal steps in the process were: 1) selection of a Working Group of 7 ESNM 
members with expertise in FD and/or Delphi consensus processes; 2) selection of an 
European Consensus Group consisting of experts in FD from different European 
countries, recruited through the ESNM board and through UEG Sister Societies; 3) 
drafting of statements allowing to evaluate the current knowledge on FD; 4) systematic 
literature reviews to identify evidence to support each statement; 5) two rounds of 
repeated voting of the statements and voting discussion until a stable level of 






For the Consensus Group, ESNM board members nominated experts from their 
respective national societies for participation, and the UEG Sister Societies (EAGEN, 
EHSMG and ESPCG) nominated additional experts. A total of 41 experts from 22 
European countries agreed to participate. Members had a background of expertise in 
gastroenterology, general practice, H. Pylori infection or gastrointestinal motility. All 
members submitted a conflict of interest statement by December 2018. 
 
The 7-member Core Group drafted and finalized a list of 75 statements covering 
several aspects of FD. The finalized list was evaluated in a first voting round by all 
members in the second quarter of 2019, where each member indicated the degree of 
agreement for the statement using a 6-point Likert scale (Table 1). Participants were 
blinded to the votes of other participants and also gave feedback on clarity of the 
statement and made suggestions for adapting or splitting the statements into 2 or more 
questions, or for adding additional statements on a given topic. The Core Group 
adjusted the statement list, generating a total of 87 statements, and subdivided the 
Guideline Group members into 12 Working Groups with 3 to 4 members each. Each 
Working Group was allocated statements for which they needed to conduct a 
systematic literature search using several relevant keywords and provide narrative 
substantiation of the statements. The literature review and references were made 
available on a share-point server, accessible to all members. This was finalized by the 
Summer of 2019, followed by a voting round in which each statement was presented 
with the evidence summary. Available members of the Guideline Group met in 
September 2019 at the occasion of the ESNM meeting in Lisbon and in October 2019 
at the UEG week in Barcelona, to discuss statements and voting outcomes. A final 
voting round was conducted between both meetings, focusing on statements that were 
adapted based on the evaluation at the ESNM meeting. Throughout the process, all 
votes were mutually anonymous and blinded. 
 
When 80% of the Consensus Group agreed (A+ or A) with a statement, this was 
defined as consensus. The strength of evidence for each statement was scored using 
the GRADE system (Table 2) (9). After the final voting round, the manuscript was 
drafted and circulated for final approval by the participants. The references cited in this 









1. Definitions and symptom descriptors 
1.1. Dyspepsia refers to a symptom or set of symptoms that is (are) considered 
to originate from the gastroduodenal region. 
STATEMENT ENDORSED, overall agreement 98%: A+ 78%, A 20%, A- 0%, D- 2%, 
D 0%, D+ 0%. GRADE B 
1.2. Early satiation, postprandial fullness, epigastric pain and epigastric burning 
are the cardinal dyspeptic symptoms as defined by Rome IV. 
STATEMENT ENDORSED, overall agreement 98%: A+ 83%, A 15%, A- 0%, D- 2%, 
D 0%, D+ 0%. GRADE B  
1.3. Functional dyspepsia is a condition characterized by chronic dyspeptic 
symptoms in the absence of organic, systemic or metabolic condition(s) that is 
(are) likely to explain symptoms 
STATEMENT ENDORSED, overall agreement 93%: A+ 68%, A 25%, A- 7%, D- 0%, 
D 0%, D+ 0%. GRADE A  
1.4. The vast majority of patients with dyspeptic symptoms and no alarm 
symptoms in the general population is identified as functional dyspepsia after 
investigation (if this would be done). 
STATEMENT ENDORSED, overall agreement 93%: A+ 66%, A 27%, A- 2%, D- 0%, 
D 5%, D+ 0%. GRADE A  
1.5. Two main subtypes of functional dyspepsia are distinguished which may 
overlap: postprandial distress syndrome (PDS) characterized by meal-induced 
symptoms (early satiation, postprandial fullness) and epigastric pain syndrome 
(EPS), with epigastric pain and/or epigastric burning not necessarily associated 
with a meal. 
STATEMENT ENDORSED, overall agreement 98%: A+ 78%, A 20%, A- 2%, D- 0%, 
D 0%, D+ 0%. GRADE B  
1.6. Dyspeptic symptoms often co-exist with other symptoms such as bloating 
in the upper abdomen, nausea and belching. 
STATEMENT ENDORSED, overall agreement 98%: A+ 73%, A 25%, A- 0%, D- 2%, 
D 0%, D+ 0%. GRADE A 
1.7. Bloating or visible distention in the upper abdomen is a dyspeptic symptom. 
STATEMENT NOT ENDORSED, overall agreement 61%: A+ 27%, A 34%, A- 29%, D- 
0%, D 5%, D+ 5%. GRADE B  





 STATEMENT NOT ENDORSED, overall agreement 76%: A+ 27%, A 49%, A- 24%, 
D- 0%, D 0%, D+ 0%. GRADE C  
1.9. Typical reflux symptoms (heartburn, regurgitation) often co-exist with 
dyspeptic symptoms in the general population. 
STATEMENT ENDORSED, overall agreement 98%: A+ 56%, A 42%, A- 2%, D- 0%, 
D 0%, D+ 0%. GRADE A  
1.10. Gastro-esophageal reflux disease may be distinguished from functional 
dyspepsia using dedicated questionnaires or good history taking. 
STATEMENT NOT ENDORSED, overall agreement 46%: A+ 14%, A 32%, A- 24%, D- 
10%, D 17%, D+ 2%. GRADE C  
1.11. Irritable bowel syndrome often coexists with functional dyspepsia. 
STATEMENT ENDORSED, overall agreement 95%: A+ 73%, A 22%, A- 5%, D- 0%, 
D 0%, D+ 0%. GRADE A 
 
The definition of dyspepsia, and FD, has seen major evolutions over time. While early 
definitions included esophageal symptoms such as heartburn, as well as nausea, 
vomiting and belching within the dyspeptic symptom complex, the Rome III and Rome 
IV consensus have significantly narrowed the symptom profile (1,3,10). The recent 
Rome IV consensus, which defined dyspepsia as the presence of chronic symptoms 
thought to originate from the gastroduodenal region, is well accepted (1). According to 
this consensus, the four cardinal dyspeptic symptoms are troublesome postprandial 
fullness, early satiation, epigastric pain and non-radiating epigastric burning (1).  
 
FD is defined as the presence of chronic dyspeptic symptoms in the absence of organic 
disease that readily explains the symptoms (1). Symptoms do not reliably distinguish 
between functional and organic dyspepsia (1,12). Consequently, in clinical practice, 
upper endoscopy is regularly performed to rule out organic causes. The prevalence of 
clinically significant endoscopic findings in subjects with uninvestigated dyspepsia is 
low, but given the high number of affected patients, relevant. Less than 10% of patients 
have a peptic ulcer and less than 1% have gastroesophageal cancer (4). Thus, based 
on the endoscopic findings, a systematic review and meta-analysis found that more 
than 70% of subjects with dyspeptic symptoms qualify for a diagnosis of FD (4). 
 
Besides the four cardinal symptoms, nausea, belching and upper abdominal bloating 
are often found in FD patients and are considered adjunctive features of the FD 
spectrum (1). Their presence may reflect common pathophysiological mechanisms 





The Rome IV criteria stress that heartburn is not a dyspeptic symptom but may often 
coexist with FD and that the presence of heartburn should not lead to the exclusion of 
FD as diagnosis (1,3). Overall, one third of FD patients also experience typical 
symptoms of gastroesophageal reflux disease (GERD) (13). It seems that, in cases of 
overlap between FD and GERD, FD is often underestimated, favoring the diagnosis of 
GERD (14). The substantial overlap of core symptoms of GERD and FD persists, 
regardless of the use of objective tools or evidence from upper endoscopies or 
esophageal pH studies (12,14). Thus, separating out GERD and FD based on 
questionnaires and history taking alone can be quite difficult if not impossible (13,15). 
In addition, non-acid related conditions such as functional heartburn frequently overlap 
with FD (13,16). Irritable bowel syndrome (IBS) is another symptomatic condition which 
frequently overlaps with FD (17). The high rate of overlap between FD and conditions 
like IBS or GERD may be explained by common etiological risk factors (e.g. acute 
infectious gastroenteritis, psychological disturbances) and pathophysiological 
mechanisms (e.g. visceral hypersensitivity, altered motility etc.) (13,15-17). Severity 
and impact of symptoms is higher in those with overlapping conditions (40). 
 
Over time, several subdivisions of the dyspeptic symptom pattern have also been 
proposed (1,3,10). According to the Rome III consensus, and refined in Rome IV, two 
subgroups are identified within FD: the postprandial distress syndrome (PDS) and the 
epigastric pain syndrome (EPS) (1,10). The PDS subgroup is characterized by 
symptom triggered or aggravated by a meal and includes postprandial fullness, early 
satiation and other postprandial symptoms. The EPS subtype is defined by meal-
unrelated symptoms, such as epigastric pain and epigastric burning (1). The existence 
of these subtypes in the general population is supported by epidemiological data (3). 
With the Rome III definitions, major overlap between EPS and PDS was found, but this 
is substantially decreased with the Rome IV update (1,3,10,11,40). 
 
Assessing the presence of cardinal and accessory symptoms requires accurate 
understanding of symptom descriptors by the patient. It may be difficult for patients to 
distinguish upper gastrointestinal symptoms based on verbal descriptors alone, but 
adding pictograms to verbal descriptors significantly improves the accuracy of 




(tertiary care, Belgium), confirmatory studies in a different medical and cultural-




2. Epidemiology and risk factors 
2.1. (Functional) Dyspepsia occurs at all ages but the highest incidence is in the 
middle age. 
STATEMENT NOT ENDORSED, overall agreement 73%: A+ 24%, A 49%, A- 24%, D- 
2%, D 0%, D+ 0%. GRADE B  
2.2. (Functional) Dyspepsia is more prevalent in women than men  
STATEMENT ENDORSED, overall agreement 83%: A+ 51%, A 32%, A- 15%, D- 0%, 
D 3%, D+ 0%. GRADE A  
2.3. Acute gastrointestinal infection is a risk factor for development of functional 
dyspepsia.  
STATEMENT ENDORSED, overall agreement 90%: A+ 54%, A 36%, A- 5%, D- 0%, 
D 5%, D+ 0%. GRADE A  
2.4. NSAID intake is a risk factor for development of functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 61%: A+ 20%, A 41%, A- 20%, D- 
0%, D 17%, D+ 2%. GRADE C  
2.5. Antibiotic therapy is a risk factor for development of functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 37%: A+ 5%, A 32%, A- 32%, D- 
7%, D 24%, D+ 0%. GRADE C  
2.6. Anxiety is a risk factor for development of functional dyspepsia  
STATEMENT ENDORSED, overall agreement 93%: A+ 34%, A 59%, A- 7%, D- 0%, 
D 0%, D+ 0%. GRADE A  
2.7. Depression is a risk factor for development of functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 76%: A+ 27%, A 49%, A- 20%, D- 
2%, D 2%, D+ 0%. GRADE B  
2.8. Smoking is a risk factor for development of functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 37%: A+ 7%, A 30%, A- 46%, D- 
2%, D 15%, D+ 0%. GRADE C  
 
Approximately 10% of the adult population fulfills symptom-based Rome IV criteria for 
(uninvestigated) FD, and its prevalence appears to disappear with increasing age 
(2,19). In several studies, the peak incidence of FD seems to occur in the forties or 
fifties age segment (19-22). A recent meta-analysis including 55 studies revealed a 
slightly higher pooled prevalence of dyspepsia in women compared with men (19). The 
Rome Global Epidemiology Study, which used the most uniform criteria and approach, 
showed a significantly higher prevalence of (uninvestigated) Rome IV FD in women 
compared to men (2). 
 
Acute gastroenteritis is associated with an increased risk of FD, with a estimated mean 
prevalence of 9.6% in adults (23). Among pathogens suggested to be associated with 




Escherichia coli O157 and Campylobacter spp. (24-26). H. pylori does not seem to be 
a cause of PI-FD (23,27). 
 
Nonsteroidal anti-inflammatory drug (NSAID) use has been identified as a risk factor 
for dyspepsia in two population-based studies (28,29). It has been suggested that the 
development of dyspeptic symptoms during treatment with NSAIDs could be linked to 
alterations in gastric mechanosensory function (30). However, NSAID intake appears 
to be most relevant to uninvestigated dyspepsia (31). Data supporting the role of drugs 
other than NSAIDs in the pathogenesis of dyspepsia in the general population are 
lacking. A nested case–control study in Olmsted County, suggested that treatment with 
antibiotics for a non-gastrointestinal infection was associated with the development of 
functional gastrointestinal disorders (FGIDs), but this needs confirmation in other 
cohorts (32). 
 
Several cross-sectional and population-based studies have observed that anxiety is 
frequently associated with FD (33-46). Some longitudinal studies have shown that 
mood disorders may precede dyspeptic symptoms and thus predispose to FD (39,41-
43). Similarly, cross-sectional and population-based studies have observed that 
depression is frequently encountered in patients with FD (33,35-40,43-45,47,48). 
However, the Kalixanda study, an important cross-sectional study carried out in a large 
sample of patients and its longitudinal 10 years follow-up investigation, failed to find a 
clear association between depression and the risk for development of FD (41,42). 
 
Population- and endoscopy-based studies suggested an association between smoking 
and FD (20,49-51). In contrast, other population-based studies failed to find an 





3. Impact of functional dyspepsia 
3.1. Functional dyspepsia is a major source of healthcare costs. 
STATEMENT ENDORSED, overall agreement 98%: A+ 78%, A 20%, A- 2%, D- 0%, 
D 0%, D+ 0%. GRADE A  
3.2. Functional dyspepsia is a major source of self-costs to patients.  
STATEMENT ENDORSED, overall agreement 93%: A+ 64%, A 29%, A- 7%, D- 0%, 
D 0%, D+ 0%. GRADE B  
3.3. Functional dyspepsia is an important source of loss of work productivity. 
STATEMENT ENDORSED, overall agreement 88%: A+ 46%, A 42%, A- 10%, D- 2%, 
D 0%, D+ 0%. GRADE B  
3.4. Functional dyspepsia is associated with a significant decrease in quality of 
life. 
STATEMENT ENDORSED, overall agreement 100%: A+ 80%, A 20%, A- 0%, D- 0%, 
D 0%, D+ 0%. GRADE A  
3.5. Functional dyspepsia is associated with psychosocial co-morbidities such 
as anxiety and depression  
STATEMENT ENDORSED, overall agreement 100%: A+ 61%, A 39%, A- 0%, D- 0%, 
D 0%, D+ 0%. GRADE A  
3.6. Weight loss can be consequence of FD 
STATEMENT ENDORSED, overall agreement 90%: A+ 43%, A 47%, A- 8%, D- 0%, 
D 2%, D+ 0%. GRADE B  
3.7. In case of weight loss, eating disorders must be ruled out. 
STATEMENT NOT ENDORSED, overall agreement 73%: A+ 36%, A 37%, A- 19%, D- 
0%, D 7%, D+ 0%. GRADE C  
3.8. Healthcare consulting behavior in functional dyspepsia is driven by 
symptom severity and impact. 
STATEMENT ENDORSED, overall agreement 93%: A+ 42%, A 51%, A- 7%, D- 0%, 
D 0%, D+ 0%. GRADE B  
3.9. Healthcare consulting behavior in functional dyspepsia is driven by 
psychosocial co-morbidity. 
STATEMENT ENDORSED, overall agreement 80%: A+ 29%, A 51%, A- 20%, D- 0%, 
D 0%, D+ 0%. GRADE B  
3.10. Healthcare consulting behavior in functional dyspepsia is driven by access 
to the healthcare system. 
STATEMENT NOT ENDORSED, overall agreement 71%: A+ 17%, A 54%, A- 19%, D- 
0%, D 7%, D+ 0%. GRADE B  
 
Studies conducted in several parts of the world have shown that FD is associated with 
significantly elevated health expenses related to medical consultations, diagnostic 
tests and therapeutic measures (55-58). In addition, FD patients incur both direct and 
indirect costs driven by over-the-counter medications, alternative therapies, medical 




(55). Studies conducted in several parts of the world report that FD patients have 
increased absenteeism, and reduced productivity at work compared to healthy 
subjects (56,57,59). 
 
Multiple studies have shown that FD is associated with a reduction in quality of life. 
Factors found to be related with a greater reduction in quality of life are anxiety and 
depression, advanced age, female sex, severity of symptoms and low or intermediate 
cultural level (60-62). 
 
Several cross-sectional studies have shown that FD frequently coexists with anxiety 
and depression and that the severity of symptoms correlates with scores on 
psychopathology questionnaires (33-46). Furthermore, psychosocial factors, such as 
depression, history of childhood abuse and somatization, have shown to contribute to 
symptom severity more than the degree of gastric sensorimotor dysfunction (38). 
 
Weight loss occurs in a large subset of subjects with dyspeptic symptoms, and is 
closely associated with symptoms of early satiation as well as epigastric pain, both at 
the population level and in tertiary care patients (63-66). Important determinants of 
weight loss in FD are impaired accommodation and decreased nutrient volume 
tolerance (63,67). 
 
Although dyspepsia affects approximately 10% of the general population, only half of 
these ever consult a doctor for their symptoms. Dyspeptic subjects who seek 
healthcare attention have more severe, frequent and persistent dyspepsia symptoms 
(57,68-70). In addition, dyspeptic patients with high scores on anxiety and depression 
questionnaires report higher consultation rates than those with lower scores, indicating 
that psychosocial factors also influence healthcare seeking behavior (36,71). A 
longitudinal study also found that anxiety or depression precedes dyspepsia among 
consulters in a larger proportion than in non-consulters, confirming that basal 
psychosocial comorbidity is associated to healthcare seeking (71). Consultation rates 
for dyspepsia vary widely between countries and regions, suggesting that access to 
the healthcare system may influence healthcare seeking behavior (70). However, 
differences in healthcare consulting behavior are also modulated by socio-economic 
status. Several studies have shown that low socio-economic status is associated with 




4. Pathophysiology of functional dyspepsia 
4.1. Dietary factors underlie symptom generation in functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 51%: A+ 24%, A 27%, A- 34%, D- 
2%, D 10%, D+ 2%. GRADE C  
4.2. Helicobacter pylori is a cause of symptoms in a subgroup of patients with 
dyspepsia and normal endoscopy. 
STATEMENT ENDORSED, overall agreement 81%: A+ 37%, A 44%, A- 17%, D- 2%, 
D 0%, D+ 0%. GRADE B  
4.3. Impaired gastric accommodation is a pathophysiological mechanism in 
functional dyspepsia. 
STATEMENT ENDORSED, overall agreement 93%: A+ 51%, A 42%, A- 7%, D- 0%, 
D 0%, D+ 0%. GRADE B  
4.4. Delayed gastric emptying is a pathophysiological mechanism in functional 
dyspepsia. 
STATEMENT ENDORSED, overall agreement 85%: A+ 39%, A 46%, A- 12%, D- 0%, 
D 2%, D+ 0%. GRADE B  
4.5. Rapid gastric emptying is a pathophysiological mechanism in functional 
dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 32%: A+ 2%, A 30%, A- 46%, D- 
5%, D 15%, D+ 2%. GRADE C 
4.6. Hypersensitivity to gastric distention is a pathophysiological mechanism in 
functional dyspepsia. 
STATEMENT ENDORSED, overall agreement 93%: A+ 63%, A 30%, A- 7%, D- 0%, 
D 0%, D+ 0%. GRADE B  
4.7. Duodenal mucosal alterations are a pathophysiological mechanism in 
functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 76%: A+ 17%, A 59%, A- 20%, D- 
2%, D 0%, D+ 2%. GRADE B  
4.8. Altered gastric acid secretion is a pathophysiological mechanism in 
functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 29%: A+ 7%, A 22%, A- 32%, D- 
7%, D 32%, D+ 0%. GRADE C  
4.9. Altered release of peptide hormones is a pathophysiological mechanism in 
functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 24%: A+ 7%, A 17%, A- 49, D- 
12%, D 12%, D+ 2%. GRADE C  
4.10. Increased sensitivity to duodenal luminal content is a pathophysiological 
mechanism in functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 68%: A+ 17%, A 51%, A- 29%, D- 
0%, D 0%, D+ 2%. GRADE C  
4.11. Altered duodenal microbiota composition is a pathophysiological 




STATEMENT NOT ENDORSED, overall agreement 34%: A+ 10%, A 24%, A- 39%, D- 
12%, D 15%, D+ 0%. GRADE C  
4.12. Impaired vagus nerve function is a pathophysiological mechanism in 
functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 46%: A+ 15%, A 31%, A- 37%, D- 
5%, D 10%, D+ 2%. GRADE C  
4.13. Anxiety and stress are pathophysiological mechanisms in functional 
dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 66%: A+ 20%, A 46%, A- 24%, D- 
2%, D 7%, D+ 0%. GRADE B  
4.14. Depression is a pathophysiological mechanism in functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 54%: A+ 15%, A 39%, A- 24%, D- 
7%, D 12%, D+ 2%. GRADE B  
4.15. Disordered central processing of incoming signals from the 
gastroduodenal region is a pathophysiological mechanism in functional 
dyspepsia. 
STATEMENT ENDORSED, overall agreement 85%: A+ 39%, A 46%, A- 12%, D- 0%, 
D 2%, D+ 0%. GRADE C  
4.16. Genetic factors determine the susceptibility to functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 37%: A+ 22%, A 15%, A- 42%, D- 
5%, D 15%, D+ 2%. GRADE C  
 
Several studies, both in community-based and in-patient cohorts, have shown that food 
is a major trigger for FD symptoms (57,73,74). Whether alterations in content or timing 
of meals in FD contributes to this triggering effect has been evaluated in only a few 
studies. A number of studies reported intake of a lower number of meals in FD patients 
compared to controls, in some cases with a tendency for more snacks between meals 
(75-77). In terms of macronutrient intake, reduced fat intake has been reported in FD 
(77), but also reduced carbohydrate has been reported in a mixed FD/IBS population 
(78). A recent systematic review of 16 studies failed to show a consistent link between 
symptoms and dietary intake (79). Taken together, there are not enough data to 
confirm that the dietary habits induce symptoms in FD patients, but patients are likely 
to have adapted their food intake patterns in an attempt to decrease symptom 
occurrence and severity. 
 
In FD patients with otherwise normal macroscopic findings at endoscopy, microscopic 
H. pylori infection has been considered a factor potentially involved in symptom 
generation. A cause effect relationship between H. pylori infection and FD is supported 




a subset of patients (80). The Kyoto consensus proposed that H. pylori infection is 
associated with dyspepsia in a subset of patients, with a strong grade of 
recommendation and high evidence level, and referred to this entity as H. pylori -
associated dyspepsia (81). The Rome IV consensus has adopted this view (1). 
However, there is a possibility of intermittent peptic ulcer disease, missed at endoscopy 
for dyspeptic symptoms (81,82). Furthermore, symptomatic improvement after 
eradication therapy may also be due to an effect of antibiotics on microbiota other than 
H. pylori infection since H. pylori eradication therapy has never been attempted in H. 
pylori -negative FD patients. 
 
Several studies have reported impaired gastric accommodation in 15 to 50% of FD 
patients (63,83-90), without differences according to Rome III subgroups (91). The 
impairment of gastric accommodation was associated with reduced drinking capacity 
and symptoms such as early satiation, fullness and weight loss (63,67,92). 
 
Several studies reported delayed gastric emptying in FD, for solids as well as liquids 
(93-100) without differences in the emptying times between Rome III subgroups (91). 
A meta-analysis described gastric emptying in patients with FD to be 1.46 times slower 
than in controls (96). Delayed gastric emptying was associated with female sex, 
postprandial fullness, nausea, vomiting, bloating and early satiety (97-100). In spite of 
the presence of delayed emptying in a subset of patients, the association with 
symptoms is weak. The severity of gastric emptying delay is not a good determinant of 
symptom severity or pattern (94,97,99,100). Few studies also reported an acceleration 
of gastric emptying in FD (101,102), but this was not confirmed in others (99). 
 
Hypersensitivity to gastric distention has been reported in 34-65% of FD patients by 
several studies (64,100-106), without difference between Rome III subgroups (91), and 
postprandial sensitivity to gastric distention was even greater than fasting sensitivity 
(107). Hypersensitivity to gastric distention was associated with a higher prevalence of 
postprandial pain, belching, and weight loss (64), and an increase in gastrointestinal 
symptom severity was observed with increasing visceral sensitivity (108). 
 
Several studies from around the world have reported increased numbers of activated 
eosinophils and mast cells in the duodenal mucosa of FD patients (109-115). In 




impaired duodenal integrity and changes in the expression of cell-to-cell adhesion 
proteins, as well as functional and structural submucosal neuronal changes (110,112). 
Although the cause-consequence relationship of the barrier defect and immune 
activation is still unknown, persisting changes in duodenal mucosal immune cells in PI-
FD and systemic immune activation in acute compared to unspecified-onset FD 
suggest the inability of the immune system to handle a triggering (infectious) insult in 
FD (116,117). 
  
Although gastric acid secretion is reported as normal (118), FD patients displayed 
increased spontaneous duodenal acid exposure during the daytime and the late 
postprandial phase with higher symptom severity in patients with high duodenal acid 
exposure (119). However, the correlation between acid exposure and symptom 
severity was weak and the increased duodenal acid exposure could be, at least in part, 
attributable to delayed duodenal acid clearance as FD patients display decreased 
duodenal motor activity in response to acid perfusion (119,120). 
 
A number of studies suggest the implication of gut hormones in the pathophysiology of 
FD, but the studies are small and findings are heterogenous (121). Early studies 
focused on cholecystokinin (CCK), as a subset of FD patients had elevated plasma 
levels, intravenous administration of CCK worsened dyspeptic symptoms and the 
selective CCKA antagonist dexloxiglumide reduced symptoms during gastric distention 
and duodenal lipid infusion (122-124). In PDS ghrelin plasma levels were reported to 
be reduced (125,126). Further studies are needed to elucidate the potential implication 
of other gut hormones including gastrin, somatostatin, glucagon-like peptide-1 and 
peptide YY in FD symptom generation (121).  
 
Duodenal hypersensitivity to luminal acid and lipids has been reported in FD (127,128), 
with induction of nausea and decreased duodenal motor responses in response to 
acid-infusion (129). These alterations were found to be chemospecific as they did not 
occur during saline or dextrose infusion (130). However, the number of studies and the 
sample size is generally low in the available studies.  
 
Data on the duodenal mucosa-associated microbiome in FD are limited to one pilot 
study involving 9 patients, with an increase in Streptococcus and decrease in the 




controls (131). Interestingly, the total mucosal bacterial load correlated with meal-
related symptom severity and quality of life, indicating the potential of targeting the 
duodenal microbiome in FD (131). Studies on the gastric microbiome in FD have 
shown a significant inverse correlation between the abundance of Prevotella in the 
gastric fluid and the severity of PDS (132). 
 
Mucosal vagal sensory nerve endings are involved in the initiation of satiety, nausea 
and vomiting by chemical and osmotic stimuli. The vagus nerve is also a major 
contributor to control upper gastrointestinal motility (133). An early study in 7 FD 
patients, using an insulin hypoglycaemia test and plasma levels of pancreatic 
polypeptide suggested a disturbed efferent vagal function (134). The gastric response 
to sham feeding, a marker for vagal activity, was lower in PDS compared to controls 
(135) and, conversely, sham feeding was reported to improve the suppressed 
response to a liquid nutrient meal in FD (136). Slow deep breathing, which is thought 
to activate the vagus nerve, was associated with improvement of nutrient volume 
tolerance and quality of life in FD (137). Using spectral analysis of cardiac R-R intervals 
to evaluate vagal tone, Guo et al. showed a decreased vagal tone that was associated 
with delayed gastric emptying (138). Taken together, a number of observations 
suggest decreased vagal activity in FD, but the studies all occurred in laboratory 
settings in small groups of patients. 
 
 As mentioned above, there is an association of anxiety with FD, and anxiety may 
precede FD. Moreover, FD is associated with altered brain processing of 
gastrointestinal (GI) stimuli, altered central nervous system connectivity and structure 
and altered expression of neurotransmitter pathways (139-143). However, a causal 
relation between anxiety and FD has not been established. As mentioned above, 
depression is also associated with FD, but also in this case, there is a lack of evidence 
for a causal relation. 
 
Numerous studies have shown that FD patients report more symptoms or earlier 
symptoms following gastro-duodenal stimulation with either balloon, liquid volume, or 
food compared to healthy controls. A systematic review evaluated studies on central 
processing of signals from the gastroduodenal region in FD patients and controls, 
mostly by balloon distention of the stomach, using PET or fMRI technology (144). The 




modulation, emotion, saliency, and homeostatic processing regions, suggesting that 
disordered central processing of incoming signals from the gastroduodenal region is 
indeed a relevant pathophysiological mechanism at least in a subgroup of FD patients. 
However, this does not exclude involvement of peripheral mechanisms as well.  
 
Family studies support a genetic component in FD susceptibility (145). A meta-analysis 
of 8 studies indicated that the GNβ3 C825T polymorphism is significantly associated 
with FD, and susceptible to racial variation (146). However, a meta-analysis based on 
12 studies has failed to confirm a significant association (147). Several additional gene 
polymorphisms including serotonin transporter promoter, interleukin-17F, migration 
inhibitory factor, cholecystokinin-1 intron 1, cyclooxygenase-1, catechol-o-
methyltransferase, transient receptor potential vanilloid 1 receptor, regulated upon 
activation normal T cell expressed and secreted, p22PHOX, Toll like receptor 2, 
SCN10A, CD14, adrenoreceptors and others have been investigated in relation to FD; 






5.1. Upper gastrointestinal endoscopy is mandatory for establishing a diagnosis 
of functional dyspepsia. 
STATEMENT ENDORSED, overall agreement 80%: A+ 51%, A 29%, A- 15%, D- 0%, 
D 2%, D+ 2%. GRADE A  
5.2. In primary care, uninvestigated dyspepsia can be managed without 
endoscopy if there are no alarm symptoms or risk factors. 
STATEMENT ENDORSED, overall agreement 93%: A+ 32%, A 61%, A- 5%, D- 0%, 
D 2%, D+ 0%. GRADE A  
5.3. Upper gastrointestinal endoscopy is mandatory if there are alarm symptoms 
or risk factors. 
STATEMENT ENDORSED, overall agreement 93%: A+ 73%, A 20%, A- 5%, D- 0%, 
D 2%, D+ 0%. GRADE A  
5.4. Screening blood tests are useful when considering a diagnosis of functional 
dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 46%: A+ 10%, A 36%, A- 24%, D- 
2%, D 24%, D+ 2%. GRADE B  
5.5. Every patient with dyspeptic symptoms should be tested for Helicobacter 
pylori (non-invasively or at gastroscopy). 
STATEMENT ENDORSED, overall agreement 81%: A+ 39%, A 42%, A- 12%, D- 0%, 
D 7%, D+ 0%. GRADE A  
5.6. Patients with dyspepsia and H. pylori positive gastritis should be considered 
to have functional dyspepsia just if symptoms persist 6 to 12 months after H. 
pylori eradication. 
STATEMENT ENDORSED, overall agreement 83%: A+ 34%, A 49%, A- 12%, D- 0%, 
D 2%, D+ 2%. GRADE B  
5.7. Patients with dyspepsia and H. pylori negative gastritis should be 
considered to have functional dyspepsia. 
STATEMENT ENDORSED, overall agreement 85%: A+ 34%, A 51%, A- 10%, D- 5%, 
D 0%, D+ 0%. GRADE B  
5.8. Functional dyspepsia should be subdivided into EPS and PDS for further 
diagnostic and therapeutic approach. 
STATEMENT ENDORSED, overall agreement 83%: A+ 34%, A 49%, A- 15%, D- 0%, 
D 2%, D+ 0%. GRADE B  
5.9. Upper abdominal ultrasound is useful when considering a diagnosis of 
functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 27%: A+ 12%, A 15%, A- 24%, D- 
10%, D 32%, D+ 7%. GRADE B  
5.10. A gastric emptying test is useful when considering a diagnosis of 
functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 34%: A+ 2%, A 32%, A- 27%, D- 




5.11. Esophageal pH monitoring is useful in functional dyspepsia to rule out 
GERD. 
STATEMENT NOT ENDORSED, overall agreement 37%: A+ 7%, A 30%, A- 29%, D- 
7%, D 24%, D+ 2%. GRADE B  
5.12. Increased duodenal eosinophil count is a marker of functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 20%: A+ 3%, A 17%, A- 37%, D- 
15%, D 27%, D+ 2%. GRADE C  
5.13. Impaired nutrient volume tolerance is a marker of functional dyspepsia. 
STATEMENT NOT ENDORSED, overall agreement 63%: A+ 14%, A 49%, A- 22%, D- 
5%, D 7%, D+ 2%. GRADE B  
 
A distinction should be made between the management of uninvestigated dyspeptic 
symptoms and the diagnosis of FD. The Rome IV definition of FD implies that potential 
underlying organic disorders have been ruled out by endoscopy (1). In a patient 
presenting with dyspeptic symptoms, all guidelines recommend a prompt upper GI 
endoscopy in patients aged over 45 to 60 years to rule out neoplasia, and to take 
biopsies to establish H. pylori status (1,10,149,150). Endoscopy is also mandatory in 
younger patients presenting with alarm features (1,10), although alarm symptoms have 
a limited value in predicting an organic disease (5,151). In younger patients without 
alarming symptoms, guidelines agree that there is no need to perform a gastroscopy 
to detect malignancy, which is rare. Empiric therapy, either with proton pump inhibitors 
(PPIs), prokinetics or H. pylori eradication (“test and treat strategy”), is valuable for the 
management of uninvestigated dyspepsia. When considering the actual diagnosis of 
FD, endoscopy is mandatory to rule out not only malignancies, but also benign organic 
disorders which may explain the symptoms such as peptic ulcer (prevalence 8%), 
esophagitis (20%), or H. pylori associated gastritis (6). The cutoff between young and 
old is now considered to be 60 years in the West, adjusted to additional risk factors 
and local incidence age of gastric cancer (150). 
 
Overall, there is a lack of data on cost-benefit utility of laboratory testing in patients 
presenting with dyspeptic symptoms. A study from India found that apart from warning 
signs, blood tests for hemoglobin and albumin could discriminate functional from 
organic disease when placed in a risk model (152), but the results have not been 
replicated in Western populations. 
 
Most Western guidelines advocate testing for H. pylori in dyspeptic subjects and 




way to manage dyspeptic patients is to reduce or stop NSAID medication and/or to 
have a non-invasive test for H. pylori (153,154). Especially in high prevalence areas, 
the positive subjects should be considered for follow-up surveillance of early gastric 
cancer (81). If endoscopy is performed, biopsies should be obtained to test for H. pylori 
status (1,10,81,149,150). 
 
H. pylori  eradication may improve symptoms in a subset of patients with investigated 
dyspepsia, i.e. with normal macroscopic upper GI endoscopy, but studies suggest that 
the symptomatic benefit is only reached after 6 to 12 months (1,81). This subgroup of 
patients, referred to as H. Pylori -associated dyspepsia, is relatively small, since meta-
analysis of randomized controlled trials has shown a 10% relative risk reduction of 
persisting symptoms in the H. Pylori eradication group compared to placebo, with a 
number needed to treat (NNT) of 12.5 to cure one case of dyspepsia (150).  
 
Although chronic superficial gastritis might affect a variety of gastric functions, there is 
no evidence to consider that the presence of gastric mucosal inflammation (with or 
without atrophy), may cause symptoms (1,81,155). Therefore, if no H. Pylori infection 
can be demonstrated, a patient with dyspeptic symptoms and normal endoscopy 
should be considered to have FD even if gastritis is present, whatever its severity (1). 
 
In population-based symptom analyses, dyspeptic symptoms were shown to group 
around clusters, representing EPS and PDS (3,156). The literature is divided on the 
usefulness of distinguishing PDS and EPS for patient management. When the Rome 
III subdivision is used, major overlap is found between both, which is largely corrected 
with the Rome IV subdivision as a good separation between both subtypes is now 
found both in epidemiological studies and in clinical practice (3,11,40,156-158). While 
some studies report different treatment responses (159,160), others do not (161,162). 
To date, no fully published study has evaluated differential pathophysiological 
mechanisms or treatment outcomes according to the Rome IV subdivision (163,164). 
 
Kraag et al. performed a meta-analysis of 21 controlled studies on the association 
between gallstones and dyspeptic symptoms and found no reasonable association 
between gallstones and ‘classical’ dyspeptic symptoms other than upper abdominal 




symptom associated to gallstones (166). Hence, guidelines do not recommend upper 
abdominal ultrasound for exclusion of biliary pathology in the diagnosis of FD (1,150). 
 
The prevalence of delayed gastric emptying in FD ranges between 20-50%, but its 
association with symptoms and response to therapy has shown inconsistent results 
(1,91,167-168). The American College of Gastroenterology and Canadian Association 
of Gastroenterology, as well as the Rome IV consensus did not recommend the use of 
gastric emptying testing in the diagnosis or management of FD (1,150). 
 
Abnormal esophageal acid exposure on pH monitoring can be found in 20 to 30% of 
patients presenting with dyspeptic symptoms without heartburn as a predominant 
symptom, and in up to 50% in the subgroup of patients with epigastric burning (13,169-
171). Randomized placebo-controlled studies have shown a small but significant 
benefit of acid-suppressive therapies (1,150). However, there is no evidence that 
esophageal pH monitoring would help to identify patients who may respond to acid-
suppressive therapy. In addition, there is no evidence that pH monitoring would be 
useful in patients with dyspeptic symptoms refractory to acid-suppressive therapy. 
 
In a systematic review and meta-analysis of 37 studies, both mast cell and eosinophil 
counts in the duodenum were increased in FD compared to controls, both in PDS and 
EPS (172). Nevertheless, as there is overlap with health and as other conditions may 
also be associated with increased eosinophil numbers, this cannot be used as a 
diagnostic marker. 
 
Several studies have reported decreased volume tolerance in FD compared to health, 
using liquid nutrients but also water intake (63,67,86,173-175). A large drinking test 
study in secondary care FD patients confirmed decreased nutrient volume tolerance, 
and this is reproducible and correlates with symptom pattern and severity (176). 
However, the use of different substances (water versus nutrients), and different rates 
of ingestion and levels of blinding to ingested nutrient volume have hampered the 





 6. Treatment 
6.1. Dietary adjustment improves symptoms in FD. 
STATEMENT NOT ENDORSED, overall agreement 73%: A+ 22%, A 51%, A- 24%, D- 
2%, D 0%, D+ 0%. GRADE C  
6.2. H. pylori positive FD patients should receive eradication therapy. 
STATEMENT ENDORSED, overall agreement 95%: A+ 59%, A 36%, A- 5%, D- 0%, 
D 0%, D+ 0%. GRADE A  
6.3. PPI therapy is the most appropriate initial therapy for FD. 
STATEMENT NOT ENDORSED, overall agreement 73%: A+ 27%, A 46%, A- 12%, D- 
2%, D 12%, D+ 0%. GRADE B  
6.4. PPI therapy is an effective therapy for FD. 
STATEMENT ENDORSED, overall agreement 83%: A+ 25%, A 58%, A- 15%, D- 2%, 
D 0%, D+ 0%. GRADE A  
6.5. PPI therapy is the most effective therapy for EPS. 
STATEMENT NOT ENDORSED, overall agreement 59%: A+ 20%, A 39%, A- 22%, D- 
2%, D 17%, D+ 0%. GRADE C  
6.6. Prokinetic therapy is the most appropriate initial therapy for FD. 
STATEMENT NOT ENDORSED, overall agreement 30%: A+ 18%, A 12%, A- 15%, D- 
12%, D 38%, D+ 5%. GRADE C  
6.7. Prokinetic therapy is an effective therapy for FD. 
STATEMENT NOT ENDORSED, overall agreement 54%: A+ 17%, A 37%, A- 34%, D- 
5%, D 7%, D+ 0%. GRADE B 
6.8. Prokinetic therapy is the most effective therapy for PDS. 
STATEMENT NOT ENDORSED, overall agreement 54%: A+ 22%, A 32%, A- 22%, D- 
5%, D 17%, D+ 2%. GRADE B  
 6.9. Efficacy of prokinetics is not related to their enhancement of gastric 
emptying rate. 
STATEMENT NOT ENDORSED, overall agreement 56%: A+ 7%, A 49%, A- 24%, D- 
7%, D 10%, D+ 2%. GRADE B  
6.10. Itopride is effective for FD patients. 
STATEMENT NOT ENDORSED, overall agreement 56%: A+ 12%, A 44%, A- 30%, D- 
7%, D 7%, D+ 0%. GRADE C 
6.11. Tricyclic antidepressants are effective for epigastric pain syndrome (EPS). 
STATEMENT NOT ENDORSED, overall agreement 78%: A+ 20%, A 58%, A- 15%, D- 
0%, D 5%, D+ 2%. GRADE B 
6.12. Tricyclic antidepressants are effective for post-prandial distress syndrome 
(PDS). 
STATEMENT NOT ENDORSED, overall agreement 32%: A+ 5%, A 27%, A- 24%, D- 
12%, D 27%, D+ 5%. GRADE B 
6.13. Tricyclic antidepressants are not effective for post-prandial distress 
syndrome (PDS). 
STATEMENT NOT ENDORSED, overall agreement 39%: A+ 10%, A 29%, A- 25%, D- 




6.14. Serotonin reuptake inhibitors are effective for FD. 
STATEMENT NOT ENDORSED, overall agreement 20%: A+ 5%, A 15%, A- 17%, D- 
12%, D 44%, D+ 7%. GRADE B 
6.15. Serotonin reuptake inhibitors are not effective for FD. 
STATEMENT NOT ENDORSED, overall agreement 54%: A+ 7%, A 47%, A- 29%, D- 
7%, D 10%, D+ 0%. GRADE B 
6.16. Serotonin noradrenaline reuptake inhibitors are effective for FD. 
STATEMENT NOT ENDORSED, overall agreement 17%: A+ 0%, A 17%, A- 27%, D- 
12%, D 39%, D+ 5%. GRADE C 
6.17. Serotonin noradrenaline reuptake inhibitors are not effective for FD. 
STATEMENT NOT ENDORSED, overall agreement 49%: A+ 5%, A 44%, A- 24%, D- 
5%, D 17%, D+ 5%. GRADE C 
6.18. Mirtazapine is effective for post-prandial distress syndrome patients with 
weight loss. 
STATEMENT NOT ENDORSED, overall agreement 68%: A+ 12%, A 56%, A- 27%, D- 
0%, D 5%, D+ 0%. GRADE B 
6.19. 5-HT1A agonists (tandospirone, buspirone, ….) are effective for PDS. 
STATEMENT NOT ENDORSED, overall agreement 56%: A+ 5%, A 51%, A- 37%, D- 
2%, D 5%, D+ 0%. GRADE B 
6.20. Herbal therapies are effective for FD patients. 
STATEMENT NOT ENDORSED, overall agreement 37%: A+ 12%, A 25%, A- 34%, D- 
10%, D 17%, D+ 2%. GRADE B 
6.21. Iberogast (STW-5) is effective for FD patients. 
STATEMENT NOT ENDORSED, overall agreement 54%: A+ 12%, A 42%, A- 34%, D- 
0%, D 12%, D+ 0%. GRADE B 
6.22. Rifaximin is effective for FD patients. 
STATEMENT NOT ENDORSED, overall agreement 19%: A+ 2%, A 17%, A- 27%, D- 
10%, D 37%, D+ 7%. GRADE C 
6.23. Hypnotherapy is effective for FD patients. 
STATEMENT NOT ENDORSED, overall agreement 29%: A+ 5%, A 24%, A- 22%, D- 
17%, D 32%, D+ 0%. GRADE B 
6.24. Cognitive behavioral therapy (CBT) is effective for FD patients. 
STATEMENT NOT ENDORSED, overall agreement 42%: A+ 10%, A 32%, A- 39%, D- 
5%, D 14%, D+ 0%. GRADE B 
6.25. Acupuncture is effective for FD patients. 
STATEMENT NOT ENDORSED, overall agreement 27%: A+ 0%, A 27%, A- 27%, D- 
15%, D 22%, D+ 10%. GRADE B 
6.26. Mindfulness is effective for FD patients. 
STATEMENT NOT ENDORSED, overall agreement 27%: A+ 3%, A 24%, A- 12%, D- 
10%, D 49%, D+ 2%. GRADE B 
6.27. In case of severe weight loss in FD, nutritional support may be needed. 
STATEMENT ENDORSED, overall agreement 90%: A+ 36%, A 54%, A- 7%, D- 0%, 





Although the majority of FD patients indicate that their symptoms are triggered by 
nutrient ingestion, there is a lack of controlled dietary intervention studies. It is 
reasonable to advise frequent small-size meals and avoiding high-fat food items, but 
the supporting evidence for this strategy is rather limited. Large‑scale randomized 
studies are required to evaluate the impact of dietary factors on symptoms of FD and 
the role of diet as a therapeutic strategy. 
 
A review of 22 trials involving 4,896 H. pylori positive FD patients showed that H. pylori 
eradication determined a small but statistically significant improvement of symptoms 
when compared with placebo (RR dyspepsia remaining=0.91; 95% CI=0.88–0.94; P 
<0.00001). The observation period in most of the trials included in the review was 12 
months and the NNT was 12.5 (150). Although the overall therapeutic effect is modest, 
additional benefits of eradication therapy are elimination of a putative pathogenic factor 
with prevention of peptic ulcer and possibly gastric cancer (1,81). Pre-Rome IV 
evidence suggests that eradication of H. pylori  infection could be beneficial in both 
predominant epigastric pain and predominant dysmotility-type symptoms, although a 
more recent study showed the main benefit in EPS (160,177). 
 
Several guidelines recommend standard, once daily PPI therapy during 4-8 weeks as 
the first-line treatment for patients with FD who remain symptomatic after eradication 
of H. pylori or who are negative for H. pylori  (150,178-180). A recent Cochrane meta-
analysis, including 6,172 patients from 18 randomized controlled trials, confirmed that 
PPIs are more effective than placebo in the reduction of global symptoms of FD (RR 
of remaining dyspeptic 0.88; 95% CI 0.82-0.94; NNT 11) (181). There were no 
differences between low or high dose PPI, type of PPI and H. pylori  status 
(150,181,182). In a meta-analysis of two studies including 740 FD patients, directly 
comparing PPI and histamin-2 receptor antagonists, there was no difference between 
both treatments (181). However, both studies are older, possibly including GERD 
patients, and one is only available in abstract form (183,184). In areas of low (<20%) 
prevalence of H. pylori , a course of PPI has been suggested as the preferred first-line 
option before a test-and-treat approach (185). The Rome IV consensus stated that 
PPIs are ineffective in relieving PDS symptoms, based on older data (1). Two 
Japanese studies that investigated the effect of PPI in the Rome III/IV subgroups, 




guidelines, based on an updated meta-analysis, propose PPI as first line therapy, 
irrespective of the Rome IV subgroups (150). 
 
A recent meta-analysis of 29 studies involving 10,044 patients with FD demonstrated 
a significant effect of prokinetics in reducing dyspeptic symptoms (RR of ongoing 
dyspeptic symptoms 0.81; 95% CI (0.74-0.89) with a NNT of 7 (187). However, the 
studies showed significant heterogeneity and the funnel plot was asymmetrical, 
suggesting publication bias. Moreover, 12 studies involved cisapride, which has been 
withdrawn from the market because of cardiac adverse events (188). When cisapride 
was removed from the meta-analysis, the overall effect was still significant, but the 
NNT increased to 12 (187). 
 
The rationale for prokinetic therapy in FD is the presence of motor abnormalities such 
as delayed gastric emptying, especially in PDS, but in a large study similar prevalence 
of gastric motor abnormalities was found in PDS, EPS and the overlap group (91). In 
the 2019 meta-analysis, prokinetics demonstrated similar efficacy in PDS and EPS 
subgroups, although only two studies included a total of 124 EPS patients (187), one 
of which is a study on cisapride from 1989 (189). The evidence supporting the use of 
prokinetics in FD is rather poor and no target subgroup can be defined based on the 
available evidence. Moreover, many prokinetics such as domperidone and acotiamide, 
are not widely available. Adverse effects, such as extrapyramidal syndrome for many 
dopamine-2 (D2) receptor antagonists and QTc prolongation with domperidone, are 
limiting chronic use in FD. This has led the ACG/CAG guideline to recommend 
treatment with a tricyclic antidepressant in patients refractory to PPI treatment, before 
prokinetics (150). 
 
A systematic analysis of 34 studies failed to demonstrate a correlation between the 
acceleration of gastric emptying and symptom improvement (167). One possible 
explanation is the heterogeneous pathophysiology of FD, involving not only delayed 
gastric emptying, but also impaired gastric accommodation and hypersensitivity to 
gastric distention which are often not taken into account. However, in a recent meta-
analysis by Vijayvargiya et al., the authors found that when optimal test methods were 
used, a selection of promotility agents significantly accelerated gastric emptying and 




Nevertheless, it has not been established that the effect of prokinetics in FD depends 
on baseline emptying rate or improvement of emptying rate with therapy. 
 
Itopride is a combined D2 antagonist and acetylcholinesterase inhibitor and is available 
in Asia and several countries in Eastern Europe. A phase IIb placebo-controlled trial 
found significantly more responders to itopride, based on a global efficacy measure 
(190) However, no significant improvement over placebo in reduction of FD symptoms 
was observed in two subsequent Phase III trials (191). These trials suffered from 
issues with patients and endpoint selection (192), but their negative outcome stopped 
further development of itopride in the West. In a recent controlled trial in Belgium, 
itopride seemed more effective in Rome IV PDS compared to Rome III PDS (193). 
 
Psychotropic drugs appear to be an effective treatment for FD, as demonstrated by a 
systematic review and meta-analysis, with an NNT of 6 when data from all studies were 
pooled (1241 patients, 673 assigned to psychoactive drugs and 568 to placebo). 
However, this beneficial effect appeared to be limited to tricyclic antidepressants (TCA) 
and antipsychotics (194). In a randomized placebo-controlled trial including 292 FD 
patients assigned to either placebo, 50 mg amitriptyline or 10 mg escitalopram for 12 
weeks, subjects with “ulcer-like” FD (likely equivalent to EPS) receiving amitriptyline 
reported more adequate relief of symptoms than those receiving placebo or 
escitalopram (p=0.06) (195). There were adverse events in 30% (n=29) individuals in 
the amitriptyline arm, leading to discontinuation of treatment in 2 of them. Those with 
delayed gastric emptying were less likely to report adequate relief on amitriptyline 
compared with FD patients with normal emptying, but this was not related to an 
amitriptyline-induced delay in gastric emptying (194). Amitriptyline appeared to derive 
its benefit predominantly through improving abdominal pain, since no change in 
psychological distress measures nor gastric emptying rates was found (195,196). In 
the subset of patients with PDS little evidence exists so far supporting the use of TCA’s. 
A double-blind, randomised controlled trial including 107 patients with refractory FD, 
treated with either imipramine or placebo for 12 weeks, showed efficacy in symptom 
relief (p=0.0051), but 18% of the patients on imipramine discontinued the study due to 
adverse effects. In this study, no conclusion was made regarding efficacy in FD 
subtypes (197). The ACG and CAG clinical guidelines on dyspepsia considered that 




offered TCA before prokinetics based on the superior evidence for TCA in this 
indication. No consideration was done based on FD subtypes EPS and PDS (150). 
 
The systematic review and meta-analysis on the efficacy of psychotropics in FD 
included two studies of selective serotonin reuptake inhibitors (sertraline 50 mg o.d. 
and escitalopram 10 mg o.d.), containing almost 400 patients, which were negative 
(194,195,198). Thus, it seems reasonable to assume that these drugs are of no benefit 
in FD. 
 
A double-blind clinical trial, randomly assigned 160 FD patients to 8 weeks of treatment 
with venlafaxine or placebo (199). At none of the measurement times there was a 
statistically significant difference in symptom severity, quality of life or anxiety and 
depression scores between venlafaxine and placebo (199). The dropout rate among 
venlafaxine treated patients was high due to side effects. While this single study with 
venlafaxine in FD was negative, it remains to be elucidated whether certain groups of 
patients, might benefit from treatment with serotonin/noradrenaline reuptake inhibitors 
with a more potent analgesic effect at lower doses, e.g. duloxetine. 
 
In FD, weight loss is normally considered an alarm symptom, but may be present in up 
to 40% of tertiary care FD patients (10,65,66). A controlled trial to assess mirtazapine’s 
efficacy in FD and weight loss randomly assigned 34 patients to placebo or mirtazapine 
15 mg daily for 8 weeks (200). Mirtazapine significantly improved early satiation scores 
and nutrient tolerance compared to placebo. A trend was found for overall dyspepsia 
symptom score at week 4 in the mirtazapine group, but not at week 8. Nevertheless, 
this was associated with significant recovery of weight loss, improvement of quality of 
life and visceral specific anxiety score. Another trial treated 60 FD patients with 
depression and weight loss with either mirtazapine 30 mg daily, paroxetine 20 mg daily 
or conventional therapy, and showed that mirtazapine did not only alleviate symptoms 
associated with dyspepsia and depression linked to FD with weight loss, but also 
significantly increased body weight (201). In summary, two limited size trials showed 
efficacy of mirtazapine in FD, one in patients without and one in patients with co-
existing depression. 
 
Tandospirone citrate, a serotonin 1A receptor (5-HT1A) agonist, was shown to improve 




agonist, failed to improve symptoms or visceral hypersensitivity in FD patients (203). 
In a small cross-over controlled trial, buspirone significantly reduced the overall 
severity of symptoms of dyspepsia and individual symptoms of postprandial fullness, 
early satiation, and upper abdominal bloating, whereas placebo had no significant 
effect (204). The presumed mechanism of action was enhancement of gastric 
accommodation (205). A meta-analysis of the 3 available studies with 5-HT1A agonists 
in FD showed no overall beneficial effect (194). 
 
Meta-analyses pooling data from different small clinical trials that fall under the FD 
category indicate that the European herbal combination drug STW-5 and peppermint-
oil are superior compared to placebo in the treatment of FD symptoms (192,206,207). 
A meta-analysis of 5 controlled trials found superiority over placebo of an encapsulated 
peppermint/caraway oil preparation in FD for overall symptoms and epigastric pain and 
discomfort (208).  
 
A meta-analysis including 24 clinical trials evaluated the efficacy of the Japanese 
herbal KAMPO preparation Rikkunshito in FD (209). No significant benefit was found 
when evaluating upper gastrointestinal symptoms based on the Gastrointestinal 
Symptom Rating Scale, but Rikkunshito was superior to placebo in improving 
symptoms based on a 5-point scale and in improving appetite, although the authors 
identified risk of bias for the majority of available studies.  
 
Meta-analyses of numerous controlled trials of low quality and small numbers of 
participants show that different Chinese Herbal Medicines, alone or in combination with 
variable prokinetic medications may be effective and superior to prokinetic medication 
alone when evaluated with variable FD symptom scores. Effects of Chinese Herbal 
Medicines on individual FD symptoms are largely unreported (210). 
 
A single double-blind, placebo-controlled randomized study examined the efficacy of 
rifaximin in subjects with Rome III criteria defined FD who were H. pylori  negative 
(211). The authors found that rifaximin was superior to placebo for the relief of global 
dyspeptic symptoms, post-prandial fullness/bloating and belching. Additional future 
trials are needed to examine the efficacy of rifaximin in FD and to elucidate the 





In a 2017 review, a total of 12 controlled trials of psychological therapies involving 
1,563 FD patients were identified (150). All trials reported a statistically significant 
benefit of psychological therapies over control, which was most commonly usual 
management. Information on individual types of psychological therapies is variable. 
For hypnotherapy in FD, only one small randomized controlled study reported benefit 
(212). For cognitive behavioral therapy, 2 studies showed positive short-term effects 
on FD symptoms (213,214). 
 
Meta-analyses of numerous low quality randomized, controlled studies suggest 
manual and electric acupuncture being effective in the treatment of FD, as shown by 
improved symptom scores and health related quality of life scores (215-217). Effects 
are most pronounced in sham controlled trials and less pronounced in trials comparing 
against prokinetic medication or traditional Chinese medicine. A recent sham 
controlled trial adds that the effect of acupuncture, following 20 treatment sessions in 
a 4 week episode, is sustained for 24 weeks (218). Besides the overall small number 
of patients included and the different acupuncture protocols followed, selection bias, 
performing bias, reporting bias, attrition bias and blinding difficulties remain the major 
concerns when interpreting findings in the meta-analyses.  
 
In a meta-analysis the quality and effectiveness of mindfulness-based therapy in 
functional gastrointestinal disorders was evaluated (219). However, studies evaluating 
the effectiveness of mindfulness specifically in FD have not been found in the literature. 
 
While severe weight loss may occur in FD patients, especially in those with PDS and 
food avoidance, few studies have addressed its management. The antidepressant 
Mirtazapine seems to help with weight-gain in these patients (200,201) and to improve 
FD symptoms, so the conclusion that other clinical management strategies for weight-
gain support may also be effective, is plausible but has not been tested. This holds 
true specifically for enteral and parenteral feeding. In one preliminary report of 19 FD 
patients with delayed gastric emptying and severe weight loss (15.8±2.8 kilograms), 
enteral feeding through a percutaneous endoscopic gastro-jejunostomy (PEG/J) 
generated weight gain in 63% of subjects, but there were many non-life-threatening 
complications. The PEG/J was electively removed after 19.9±5.6 months and a mean 





7. Prognosis of FD 
7.1. The long-term prognosis is favorable in the majority of patients with FD. 
STATEMENT ENDORSED, overall agreement 85%: A+ 29%, A 56%, A- 12%, D- 0%, 
D 2%, D+ 0%. GRADE B  
7.2. Life expectancy in FD is similar to the general population. 
STATEMENT ENDORSED, overall agreement 100%: A+ 56%, A 44%, A- 0%, D- 0%, 
D 0%, D+ 0%. GRADE A  
 
It is well established that symptoms in FD vary over time. Based on a cohort study 1 
year after initial diagnosis, 24% of patients reported their symptoms as unimproved, 
and these patients were younger and had higher symptom severity at first diagnosis 
(219). In a tertiary care cohort, half of FD patients improved or became asymptomatic 
after a mean follow-up of 5 years, with anxiety and weight loss at presentation as 
unfavorable predictors (48). Population-based reports of longer observation periods 
performed in Olmsted County, Minnesota, USA (12 years) and Iceland (10 years) 
report a favorable outcome with symptom resolution in 63-67%, stable or persistent 
symptoms falling under the FD category in 16-20% and fluctuating or additional 
symptoms in 32-35% confirming high symptom turnover amongst FGID patients 
(222,223). 
 
In a population-based cohort study 5,262 randomly selected subjects were screened. 
From 3,933 eligible subjects included in the analysis dyspepsia was diagnosed in 2% 
of subjects. No association with overall survival was detected for dyspepsia (HR = 1.08 
(95% CI: 0.58–2.02)) (224). A 10-year long-term follow-up study included 8,323 
people, of whom dyspepsia was diagnosed in 3,169 patients (38.1%). After multivariate 
analysis, there was no significant difference in likelihood of death at 10 years in those 
with dyspepsia (HR: 0.94; 99% CI: 0.58-1.54) compared to those who did not meet the 
criteria for FD (225). Thus, available data show that life expectancy in FD is similar to 







Based on the statements that achieved consensus, a number of recommendations for 
understanding and managing FD can be made, which are summarized in Table 4. The 
Delphi process also identified several areas of uncertainty, which require additional 
evidence or further research. Figure 1 schematically summarizes the findings. 
 
The Rome IV definition with 4 cardinal symptoms (early satiation, postprandial fullness, 
epigastric pain and epigastric burning), its subdivision into EPS and PDS, and 
accessory symptoms (upper abdominal bloating, nausea, belching) are well-accepted. 
There is also consensus that the majority of uninvestigated dyspepsia in the general 
population represents FD, if investigation would be done. Overlap with GERD and IBS 
is acknowledged. Also well accepted are the female predominance of FD, and acute 
gastrointestinal infections and anxiety as risk factors for developing FD. There is a 
clear consensus on the impact of FD on the personal level (quality of life, self-cost), on 
healthcare costs, on ability to work and on psychosocial wellbeing. 
 
In terms of pathophysiological mechanisms that are relevant to FD, consensus 
supports a role for impaired gastric accommodation, delayed gastric emptying, 
hypersensitivity to gastric distention, H. pylori  infection and altered central processing 
of incoming signals from the gastroduodenal region. There is no consensus on 
duodenal mucosal alterations, sensitivity to luminal contents, peptide release or 
microbiota. Anxiety is a risk factor for development of functional dyspepsia; however, 
anxiety, depression or stress are not considered pathophysiological mechanisms that 
underlie FD symptom generation. 
 
There is consensus that endoscopy is mandatory for establishing a firm diagnosis of 
FD, but that patients in primary care with dyspeptic symptoms and no alarm symptoms 
or risk factors can be managed without endoscopy. There is consensus that endoscopy 
is mandatory in case of alarm symptoms or risk factors, and that H. pylori  status should 
be determined at endoscopy or non-invasively in every patient. There is no consensus 
on benefit of additional examinations including laboratory testing, abdominal 





The biggest area of lack of consensus is the section on treatment approaches for FD. 
There is agreement to use to subdivision in PDS and EPS to guide management, but 
the vast majority of treatment options are not supported for a specific subgroup. There 
is consensus to eradicate every H. pylori  positive FD patient, and PPI therapy is 
considered an effective therapy for FD, although there is no consensus that it is the 
preferred initial therapy. There is no consensus on the indication and efficacy of 
prokinetics or antidepressants, but an almost-agreement (78%) on the use of TCA in 
EPS. There is also no consensus on the use of other neuromodulators, herbal 
therapies, acupuncture or psychological therapies in FD. There is agreement on the 
use of nutritional support in case of severe weight loss. Finally, there is consensus that 
the long-term prognosis of FD is favorable and that life expectancy is not shortened in 
FD. 
 
The areas of uncertainty revealed by this consensus are multiple. Further unraveling 
of the FD symptom pattern is useful, and especially the concept of using pictograms 
deserves additional, preferably multi-lingual and multi-cultural studies. These may aid 
further diagnostic refinement, where the currently only supported tools are endoscopy 
and H. pylori  status assessments, with their limited sensitivity and impact on 
management and outcome. While there is acceptance of a role for gastric sensorimotor 
dysfunction in triggering FD symptoms, the role of duodenal luminal or mucosal 
alterations is not established, but the 76% amount of agreement is still considerable. 
The putative entity of H. pylori-associated dyspepsia is poorly described and needs 
further characterizing studies, especially in the West. The voting on the therapy 
statements clearly establishes the need for more therapeutic trials, preferably in a 
multi-center setting using validated endpoints. In the absence of a well-established 
path to regulatory approval, scientific or professional organizations such as the 
European Society for Neurogastroenterology and Motility (ESNM) or the Rome 




FD is a highly prevalent and impactful clinical condition. This Delphi process used a 
multinational and multidisciplinary group of European experts to summarize the current 




treatment and prognosis of this condition. The Consensus Group voted on several 
statements that may guide clinicians in recognizing, diagnosing and treating FD in 
clinical practice, whereas the statements without consensus identify areas in need of 
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Figure 1: Schematic representation, in an algorithm-like fashion, of the outcome of the 
consensus on FD management. The blue arrows depict the diagnostic and therapeutic 
flow of the patient. Green arrows refer to risk or pathophysiological factors. The circles 
depict the % of agreement, using a green colour for ≥80% consensus, light orange for 







Table 1: 6-point Likert scale. 
point Description 
A+ agree strongly 
A  agree with minor reservation 
A- agree with major reservation 
D- disagree with minor reservation 
D  disagree with major reservation 






Table 2: Grading of recommendations assessment, development and evaluation 
system 9 
 
Code Quality of evidence Definition  
A High Further research is very unlikely to change our 
confidence in the estimate of effect 
• Several high-quality studies with consistent results 
• In special cases: one large, high-quality 
multicenter trial 
B Moderate Further research is likely to have an important impact 
on our confidence in the estimate of effect and may 
change the estimate. 
• One high-quality study 
• Several studies with some limitations 
C Low Further research is very likely to have an important 
impact on our confidence in the estimate of effect and 
is likely to change the estimate. 
• One or more studies with severe limitations 
D Very low Any estimate of effect is very uncertain. 
• Expert opinion 
• No direct research evidence 





Table 3: All statements with endorsement and references.  
 
Statement Endorsement Grade of 
Evidence 
References  
1.1. Dyspepsia refers to a symptom or set of symptoms that is 
(are) considered to originate from the gastro-duodenal region. 
Yes B 1-4 
1.2. Early satiation, postprandial fullness, epigastric pain and 
epigastric burning are the cardinal dyspeptic symptoms as 
defined by Rome IV. 
Yes B 1-4 
1.3. FD is a condition characterized by chronic dyspeptic 
symptoms in the absence of organic, systemic or metabolic 
condition(s) that is (are) likely to explain symptoms. 
Yes A 1-4 
1.4. The vast majority of patients with dyspeptic symptoms and 
no alarm symptoms in the general population is identified as FD 
after investigation (if this would be done). 
Yes A 1,4 
1.5. Two main subtypes of FD are distinguished which may 
overlap: postprandial distress syndrome (PDS) characterized 
by meal-induced symptoms (early satiation, postprandial 
fullness) and epigastric pain syndrome (EPS), with epigastric 
pain and/or epigastric burning not necessarily associated with 
a meal. 
Yes B 1,3,10,11 
1.6. Dyspeptic symptoms often co-exist with other symptoms 
such as bloating in the upper abdomen, nausea and belching. 
Yes A 1,7 
1.7. Bloating or visible distention in the upper abdomen is a 
dyspeptic symptom. 
No B 1,10,11 
1.8. The use of pictograms helps to characterize the presence 
and nature of dyspeptic symptoms. 
No C 18 
1.9. Typical reflux symptoms (heartburn, regurgitation) often co-
exist with dyspeptic symptoms in the general population. 
Yes A 12-16 
1.10. Gastro-esophageal reflux disease may be distinguished 
from FD using dedicated questionnaires or good history taking. 
No C 12-16 
1.11. Irritable bowel syndrome often coexists with FD. Yes A 17 
2.1. (Functional) Dyspepsia occurs at all ages but the highest 
incidence is in the middle age. 
No B 2,19-22 
2.2. (Functional) Dyspepsia is more prevalent in women than 
men  
Yes A 2,19-22 
2.3. Acute GI infection is a risk factor for development of FD.  Yes A 23-27 
2.4. NSAID intake is a risk factor for development of FD.  No C 28-31 




2.6. Anxiety is a risk factor for development of FD  Yes A 33-48 
2.7. Depression is a risk factor for development of FD. No B 33-48 
2.8. Smoking is a risk factor for development of FD. No C 49-54 
3.1. FD is a major source of healthcare costs. Yes A 55-58 
3.2. FD is a major source of self-costs to patients.  Yes B 55 
3.3. FD is an important source of loss of work productivity.  Yes B 56,57,59 
3.4. FD is associated with a significant decrease in quality of life. Yes A 60-62 
3.5. FD is associated with psychosocial co-morbidities such as 
anxiety and depression  
Yes A 33-46,48 
3.6. Weight loss can be consequence of FD Yes B 63-67 
3.7. In case of weight loss, eating disorders must be ruled out. No C 63-67 
3.8. Healthcare consulting behavior in FD is driven by symptom 
severity and impact. 
Yes B 57,68-70 
3.9. Healthcare consulting behavior in FD is driven by 
psychosocial co-morbidity. 
Yes B 36,71 
3.10. Healthcare consulting behavior in FD is driven by access 
to the healthcare system. 
No B 68,70,72 
4.1. Dietary factors underlie symptom generation in FD. No C 57,73-79 
4.2. H. pylori is a cause of symptoms in a subgroup of patients 
with dyspepsia and normal endoscopy. 
Yes B 80-82 
4.3. Impaired gastric accommodation is a pathophysiological 
mechanism in FD. 
Yes B 63,67,83-93 
4.4. Delayed gastric emptying is a pathophysiological 
mechanism in FD. 
Yes B 91,93-102 
4.5. Rapid gastric emptying is a pathophysiological mechanism 
in FD. 
No C 99,101,102 
4.6. Hypersensitivity to gastric distention is a patho-
physiological mechanism in FD. 
Yes B 64,91,100-
108 
4.7. Duodenal mucosal alterations are a patho-physiological 
mechanism in FD. 
No B 109-117 
4.8. Altered gastric acid secretion is a pathophysiological 
mechanism in FD. 
No C 118-120 
4.9. Altered release of peptide hormones is a pathophysiological 
mechanism in FD. 
No C 121-124 
4.10. Increased sensitivity to duodenal luminal content is a 
pathophysiological mechanism in FD. 
No C 127-130 
4.11. Altered duodenal microbiota composition is a 
pathophysiological mechanism in FD. 




4.12. Impaired vagus nerve function is a pathophysiological 
mechanism in FD. 
No C 133-138 
4.13. Anxiety and stress are pathophysiological mechanisms in 
FD. 
No B 33-48 
4.14. Depression is a pathophysiological mechanism in FD. No B 33-46,48 
4.15. Disordered central processing of incoming signals from 
the gastroduodenal region is a pathophysiological mechanism 
in FD. 
Yes C 139-144 
4.16. Genetic factors determine the susceptibility to FD. No C 145-148 
5.1. Upper GI endoscopy is mandatory for establishing a 
diagnosis of FD. 
Yes A 1,10,149-151 
5.2. In primary care, uninvestigated dyspepsia can be managed 
without endoscopy if there are no alarm of risk factors. 
Yes A 149-151 
5.3. Upper GI endoscopy is mandatory if there are alarm 
symptoms or risk factors. 
Yes A 1,10,149-151 
5.4. Screening blood test are useful when considering a 
diagnosis of FD. 
No B 152 
5.5. Every patient with dyspeptic symptoms should be tested for 
H. pylori (non-invasively or at gastroscopy). 
Yes A 1,10,81,149,
150,153,154 
5.6. Patients with dyspepsia and H. pylori positive gastritis 
should be considered to have FD just if symptoms persist 6 to 
12 months after H. pylori eradication. 
Yes B 1,81,155 
5.7. Patients with dyspepsia and HP negative gastritis should be 
considered to have FD. 
Yes B 1,81,155 
5.8. FD should be subdivided into EPS and PDS for further 
diagnostic and therapeutic approach. 
Yes B 3,11,40,156-
162 
5.9. Upper abdominal ultrasound is useful when considering a 
diagnosis of FD. 
No B 1,150,165-
166 
5.10. A gastric emptying test is useful when considering a 
diagnosis of FD. 
No B 1,91,150,167
-168 
5.11. Esophageal pH monitoring is useful in FD to rule out 
GERD. 
No B 13,169-171 
5.12. Increased duodenal eosinophil count is a marker of FD. No C 172 
5.13. Impaired nutrient volume tolerance is a marker of FD. No B 63,67,86,173
-176 
6.1. Dietary adjustment improves symptoms in FD. No C 57,73-79 








6.4. PPI therapy is an effective therapy for FD. Yes A 150,178-186 
6.5. PPI therapy is most effective for EPS. No C 150,177,186 
6.6. Prokinetic therapy is the most appropriate initial therapy for 
FD. 
No C 150,187-189 
6.7. Prokinetic therapy is an effective therapy for FD. No B 150,187-189 
6.8. Prokinetic therapy is most effective for PDS. No B 150,187-189 
 6.9. Efficacy of prokinetics is not related to their enhancement 
of gastric emptying rate. 
No B 150,187-189 
6.10. Itopride is effective for FD patients. No C 190-193 
6.11. Tricyclic antidepressants are effective for epigastric pain 
syndrome (EPS). 
No B 194-197 
6.12. Tricyclic antidepressants are effective for post-prandial 
distress syndrome (PDS). 
No B 194-197 
6.13. Tricyclic antidepressants are not effective for post-
prandial distress syndrome (PDS). 
No B 150,194-197 
6.14. Serotonin reuptake inhibitors are effective for FD. No B 195,198 
6.15. Serotonin reuptake inhibitors are not effective for FD. No B 195,198 
6.16. Serotonin noradrenaline reuptake inhibitors are effective 
for FD. 
No C 199 
6.17. Serotonin noradrenaline reuptake inhibitors are not 
effective for FD. 
No C 199 
6.18. Mirtazapine is effective for post-prandial distress 
syndrome patients with weight loss. 
No B 200,201 
6.19. 5-HT1A agonists (tandospirone, buspirone, ….) are 
effective for PDS. 
No B 202-206 
6.20. Herbal therapies are effective for FD patients. No B 209-210 
6.21. Iberogast (STW-5) is effective for FD patients. No B 192,206,207 
6.22. Rifaximin is effective for FD patients. No C 211 
6.23. Hypnotherapy is effective for FD patients. No B 212 
6.24. Cognitive behavioral therapy (CBT) is effective for FD 
patients. 
No B 213,214 
6.25. Acupuncture is effective for FD patients. No B 215-218 
6.26. Mindfulness is effective for FD patients. No B 219 
6.27. In case of severe weight loss in FD, nutritional support may 
be needed. 
Yes B 220 
7.1. The long-term prognosis is favorable in the majority of 
patients with FD. 
Yes B 49;221,222 





Table 4: Summary of the ESNM consensus on FD.  
 
Recommendations Based on 
statement(s) 
Dyspepsia refers to a symptom or set of symptoms that are considered to 
originate from the gastroduodenal region. Early satiation, postprandial fullness, 
epigastric pain and epigastric burning are the cardinal dyspeptic symptoms. 
1.1, 1.2 
FD is a condition characterized by chronic dyspeptic symptoms in the absence 
of organic, systemic or metabolic condition(s) that is (are) likely to explain 
symptoms. The vast majority of patients with dyspeptic symptoms and no alarm 
symptoms in the general population would be identified as FD after investigation 
(if performed). 
1.3, 1.4 
Two main subtypes of FD are distinguished which may overlap: postprandial 
distress syndrome (PDS) characterized by meal-induced symptoms (early 
satiation, postprandial fullness) and epigastric pain syndrome (EPS), with 
epigastric pain and/or epigastric burning. 
1.5 
Dyspeptic symptoms often co-exist with other symptoms such as bloating in the 
upper abdomen, nausea and belching. Typical reflux symptoms and irritable 
bowel syndrome often coexists with FD. 
1.6, 1.9, 1.11 
(Functional) Dyspepsia is more prevalent in women than men. 2.2 
Acute GI infection and anxiety are risk factors for development of FD. 2.3; 2.6 
FD is a major source of healthcare costs, self-costs to patients and loss of work 
productivity. 
3.1, 3.2, 3.3 
FD is associated with a significant decrease in quality of life and with 
psychosocial co-morbidities. 
3.4,3.5 
Weight loss can be consequence of FD. 3.6 
Healthcare consulting behavior in FD is driven by symptom severity and impact, 
and by psychosocial co-morbidities.  
3.8,3.9 






Impaired gastric accommodation, delayed gastric emptying, hypersensitivity to 
gastric distention and disordered central processing of incoming signals from the 
gastroduodenal region are pathophysiological mechanisms in FD 
4.3, 4.4, 4.6, 4.15 
Upper GI endoscopy is mandatory for establishing a diagnosis of FD, but in 
primary care, dyspepsia can be managed without endoscopy if there are no 
alarm of risk factors. The endoscopy is mandatory if there are alarm symptoms 
or risk factors 
5.1, 5.2, 5.3 
Every patient with dyspeptic symptoms should be tested for H. pylori (Hp) (non-
invasively or at gastroscopy). H. pylori positive FD patients should receive 
eradication therapy. Patients with dyspepsia and H. pylori positive gastritis 
should be considered to have FD if symptoms persist 6 to 12 months after H. 
pylori eradication. Patients with dyspepsia and H. pylori negative gastritis should 
be considered to have FD. 
5.5, 5.6, 5.7, 6.2 
FD should be subdivided into EPS and PDS for further diagnostic and 
therapeutic approach 
5.8 
PPI-therapy is an effective therapy for FD. 6.4 
In case of severe weight loss in FD, nutritional support may be needed. 6.27 
The long-term prognosis is favorable in the majority of patients with FD, whose 
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